Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
Eur J Pharmacol ; 409(3): 301-12, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11108825

ABSTRACT

L-771,688 (SNAP 6383, methyl(4S)-4-(3, 4-difluorophenyl)-6-[(methyloxy)methyl]-2-oxo-3-[(¿3-[4-(2-pyridin yl)-1-piperidinyl]propyl¿amino)carbonyl]-1,2,3, 4-tetrahydro-5-pyrimidine carboxylate) had high affinity (Ki less than or = 1 nM) for [3H]prazosin binding to cloned human, rat and dog alpha1A-adrenoceptors and high selectivity (>500-fold) over alpha1B and alpha1D-adrenoceptors. [3H]Prazosin / (+/-)-beta-[125I]-4-hydroxy-phenyl)-ethyl-aminomethylteralone ([125I]HEAT) binding studies in human and animal tissues known to contain alpha1A and non-alpha1A-adrenoceptors further demonstrated the potency and alpha1A-subtype selectivity of L-771,688. [3H]L-771,688 binding studies at the cloned human alpha1A-adrenoceptors and in rat tissues indicated that specific [3H]L-771,688 binding was saturable and of high affinity (Kd=43-90 pM) and represented binding to the pharmacologically relevant alpha1A-adrenoceptors. L-771,688 antagonized norepinephrine-induced inositol-phosphate responses in cloned human alpha1A-adrenoceptors, as well as phenylephrine or A-61603 (N-[5-4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7, 8-terahydro-naphthlen-1-yl] methanesulfonamide hydrobromide) induced contraction in isolated rat, dog and human prostate, human and monkey bladder neck and rat caudal artery with apparent Kb values of 0.02-0.28 nM. In contrast, the contraction of rat aorta induced by norepinephrine was resistant to L-771,688. These data indicate that L-771,688 is a highly selective alpha1A-adrenoceptor antagonist.


Subject(s)
Adrenergic alpha-Antagonists/metabolism , Prazosin/metabolism , Prostate/metabolism , Pyrimidinones/metabolism , Receptors, Adrenergic, alpha-1/metabolism , Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Agonists/metabolism , Animals , Dogs , Humans , Imidazoles/metabolism , Male , Phenylephrine/metabolism , Prazosin/analogs & derivatives , Rats , Tetrahydronaphthalenes/metabolism , Urinary Bladder/metabolism
3.
Bioorg Med Chem Lett ; 10(15): 1621-4, 2000 Aug 07.
Article in English | MEDLINE | ID: mdl-10937709

ABSTRACT

A novel class of potent and selective alpha-1a receptor antagonists has been identified. The structures of these antagonists were derived from truncating the 4-aryl dihydropyridine subunit present in known alpha-1a antagonists. The design principles which led to the discovery of substituted phenylacetamides, the synthesis and SAR of key analogues, and the results of select in vitro and in vivo studies are described.


Subject(s)
Acetamides/pharmacology , Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/pharmacology , Acetamides/chemistry , Acetamides/pharmacokinetics , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Dogs , Structure-Activity Relationship
4.
J Med Chem ; 43(14): 2703-18, 2000 Jul 13.
Article in English | MEDLINE | ID: mdl-10893308

ABSTRACT

alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K(i) values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1b) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.


Subject(s)
Adrenergic alpha-Antagonists/chemical synthesis , Pyrimidinones/chemical synthesis , Receptors, Adrenergic, alpha-1/drug effects , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/pharmacokinetics , Adrenergic alpha-Antagonists/pharmacology , Animals , Biological Availability , Caco-2 Cells , Crystallography, X-Ray , Dogs , Humans , Male , Prostatic Hyperplasia/drug therapy , Pyrimidinones/chemistry , Pyrimidinones/metabolism , Pyrimidinones/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, alpha-1/metabolism , Structure-Activity Relationship
5.
Bioorg Med Chem Lett ; 10(2): 175-8, 2000 Jan 17.
Article in English | MEDLINE | ID: mdl-10673105

ABSTRACT

Furo[3,4-d]pyrimidinones were found to be metabolites of dihydropyrimidinones such as 1a-b that are subtype-selective antagonists of the alpha1a-adrenergic receptor. A versatile synthesis that provides access to furo[3,4-d]pyrimidinones in high yield and in enantiomerically pure forms is described along with structure-activity relationships in the series.


Subject(s)
Adrenergic alpha-Antagonists/chemical synthesis , Pyrimidinones/chemical synthesis , Receptors, Adrenergic, alpha-1/drug effects , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding, Competitive , Molecular Structure , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Prazosin/metabolism , Pyrimidinones/pharmacology , Rats , Stereoisomerism , Structure-Activity Relationship
6.
J Med Chem ; 42(23): 4764-77, 1999 Nov 18.
Article in English | MEDLINE | ID: mdl-10579840

ABSTRACT

Dihydropyrimidinones such as compound 12 exhibited high binding affinity and subtype selectivity for the cloned human alpha(1a) receptor. Systematic modifications of 12 led to identification of highly potent and subtype-selective compounds such as (+)-30 and (+)-103, with high binding affinity (K(i) = 0.2 nM) for alpha(1a) receptor and greater than 1500-fold selectivity over alpha(1b) and alpha(1d) adrenoceptors. The compounds were found to be functional antagonists in human, rat, and dog prostate tissues. Compound (+)-103 exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (K(b)(DBP)/K(b)(IUP) = 40) suggesting uroselectivity for alpha(1a)-selective compounds.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/chemical synthesis , Pyrimidinones/chemical synthesis , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding, Competitive , Blood Pressure/drug effects , Dogs , Drug Design , Drug Evaluation, Preclinical , Humans , In Vitro Techniques , Male , Prostate/metabolism , Pyrimidinones/chemistry , Pyrimidinones/metabolism , Pyrimidinones/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, alpha-1/metabolism , Stereoisomerism , Urethra/drug effects , Urethra/physiology
7.
J Med Chem ; 42(23): 4778-93, 1999 Nov 18.
Article in English | MEDLINE | ID: mdl-10579841

ABSTRACT

We have previously described compound 1a as a high-affinity subtype selective alpha(1a) antagonist. In vitro and in vivo evaluation of compound 1a showed its major metabolite to be a mu-opioid agonist, 4-methoxycarbonyl-4-phenylpiperidine (3). Several dihydropyrimidinone analogues were synthesized with the goal of either minimizing the formation of 3 by modification of the linker or finding alternative piperidine moieties which when cleaved as a consequence of metabolism would not give rise to mu-opioid activity. Modification of the linker gave several compounds with good alpha(1a) binding affinity (K(i) = < 1 nM) and selectivity (>300-fold over alpha(1b) and alpha(1d)). In vitro analysis in the microsomal assay revealed these modifications did not significantly affect N-dealkylation and the formation of the piperidine 3. The second approach, however, yielded several piperidine replacements for 3, which did not show significant mu-opioid activity. Several of these compounds maintained good affinity at the alpha(1a) adrenoceptor and selectivity over alpha(1b) and alpha(1d). For example, the piperidine fragments of (+)-73 and (+)-83, viz. 4-cyano-4-phenylpiperidine and 4-methyl-4-phenylpiperidine, were essentially inactive at the mu-opioid receptor (IC(50) > 30 microM vs 3 microM for 3). Compounds (+)-73 and (+)-83 were subjected to detailed in vitro and in vivo characterization. Both these compounds, in addition to their excellent selectivity (>880-fold) over alpha(1b) and alpha(1d), also showed good selectivity over several other recombinant human G-protein coupled receptors. Compounds (+)-73 and (+)-83 showed good functional potency in isolated human prostate tissues, with K(b)s comparable to their in vitro alpha(1a) binding data. In addition, compound (+)-73 also exhibited good uroselectivity (DBP K(b)/IUP K(b) > 20-fold) in the in vivo experiments in dogs, similar to 1a.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/chemical synthesis , Piperidines/chemical synthesis , Pyrimidinones/chemical synthesis , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , Biological Availability , Blood Pressure/drug effects , Dogs , Drug Design , Drug Evaluation, Preclinical , GTP-Binding Proteins/metabolism , Half-Life , Humans , In Vitro Techniques , Male , Microsomes/metabolism , Piperidines/chemistry , Piperidines/metabolism , Piperidines/pharmacology , Prostate/metabolism , Pyrimidinones/chemistry , Pyrimidinones/metabolism , Pyrimidinones/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, alpha-1/metabolism , Receptors, Opioid, mu/agonists , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship , Urethra/drug effects , Urethra/physiology
8.
J Med Chem ; 42(23): 4794-803, 1999 Nov 18.
Article in English | MEDLINE | ID: mdl-10579842

ABSTRACT

Dihydropyrimidinones, such as 1, represent a novel class of alpha(1a) adrenoceptor antagonists with potential for the treatment of benign prostatic hyperplasia (BPH) (see part 1 of this series). Analysis of the metabolites of 1 revealed that 4-methoxycarbonyl-4-phenylpiperidine is formed as the major metabolite and is an agonist at the mu-opioid receptor. To circumvent any potential liability resulting from the metabolite, we decided to identify alternate templates devoid of agonist activity at the mu-opioid receptor to replace the 4-methoxycarbonyl-4-phenylpiperidine moiety. The present study describes the synthesis and SAR of dihydropyrimidinones linked to substituted 4-phenylpiperazine containing side chains. Compound (+)-38 was identified as a lead compound with a binding and functional profile comparable to that of 1. The putative metabolite 2-carboxamidophenylpiperazine has negligible affinity for the mu-opioid receptor.


Subject(s)
Adrenergic alpha-Antagonists/chemical synthesis , Piperazines/chemical synthesis , Pyrimidinones/chemical synthesis , Receptors, Adrenergic, alpha-1/metabolism , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding, Competitive , Biological Availability , Dogs , Drug Design , GTP-Binding Proteins/metabolism , Half-Life , Humans , In Vitro Techniques , Male , Piperazines/chemistry , Piperazines/metabolism , Piperazines/pharmacology , Prostate/metabolism , Pyrimidinones/chemistry , Pyrimidinones/metabolism , Pyrimidinones/pharmacology , Rats , Receptors, Opioid, mu/agonists , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship
9.
J Med Chem ; 42(23): 4804-13, 1999 Nov 18.
Article in English | MEDLINE | ID: mdl-10579843

ABSTRACT

We have previously disclosed dihydropyridines such as 1a,b as selective alpha(1a) antagonists as a potential treatment for benign prostatic hyperplasia (BPH). The propensity of dihydropyridines toward an oxidation led us to find suitable replacements of the core unit. The accompanying papers describe the structure-activity relationship (SAR) of dihydropyrimidinones 2a,b as selective alpha(1a) antagonists. We report herein the SAR of dihydropyrimidines such as 4 and highlight the similarities and differences between the dihydropyrimidine and dihydropyrimidinone series of compounds.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/chemical synthesis , Pyrimidines/chemical synthesis , Administration, Oral , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding, Competitive , Biological Availability , Dogs , Drug Design , Drug Evaluation, Preclinical , Humans , In Vitro Techniques , Male , Prostate/metabolism , Pyrimidines/chemistry , Pyrimidines/metabolism , Pyrimidines/pharmacology , Rats , Receptors, Adrenergic, alpha-1/metabolism , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship
10.
Bioorg Med Chem Lett ; 9(19): 2843-8, 1999 Oct 04.
Article in English | MEDLINE | ID: mdl-10522703

ABSTRACT

A series of analogs of SNAP 5150 containing heteroatoms at C2 or C6 positions is described. Herein, we report that the presence of alkyl substituted heteroatoms at the C2(6)-positions of the dihydropyridine are well tolerated. In addition, 15 inhibited the phenylephrine induced contraction of dog prostate tissue with a Kb of 1.5 nM and showed a Kb (DBP, dogs, microg/kg)/Kb (IUP, dogs, microg/kg) ratio of 14.8/2.5.


Subject(s)
Adrenergic Antagonists/chemical synthesis , Dihydropyridines/chemical synthesis , Adrenergic Antagonists/pharmacology , Animals , Calcium Channels/metabolism , Dihydropyridines/pharmacology , Dogs , Humans , Male , Molecular Structure , Phenylephrine/pharmacology , Prostate/drug effects , Prostatic Hyperplasia/drug therapy , Protein Binding , Rats , Stereoisomerism
11.
J Med Chem ; 41(26): 5320-33, 1998 Dec 17.
Article in English | MEDLINE | ID: mdl-9857099

ABSTRACT

We report the synthesis and evaluation of novel alpha1a adrenoceptor subtype-selective antagonists. Systematic modification of the lipophilic 4,4-diphenylpiperidinyl moiety of the dihydropyridine derivatives 1 and 2 provided several highly selective and potent alpha1a antagonists. From this series, we identified the 4-(methoxycarbonyl)-4-phenylpiperidine analogue SNAP 5540 (-) [(-)-63] for further characterization. When examined in an isolated human prostate tissue assay, this compound was found to have a Ki of 2.8 nM, in agreement with the cloned human receptor binding data (Ki = 2.42 nM). Further evaluation of the compound in isolated dog prostate tissue showed a Ki of 3.6 nM and confirmed it to be a potent antagonist (Kb = 1.6 nM). In vivo, this compound effectively blocked the phenylephrine-stimulated increase in intraurethral pressure (IUP) in mongrel dogs, at doses which did not significantly affect the arterial pressure (diastolic blood pressure, DBP), with a DBP Kb/IUP Kb ratio of 16. In addition, (-)-63 also showed greater than 40 000-fold selectivity over the rat L-type calcium channel and 200-fold selectivity over several G protein-coupled receptors, including histamine and serotonin subtypes. These findings prove that alpha1a adrenoceptor-subtype selective antagonists such as (-)-63 may be developed as uroselective agents for an improved treatment of BPH over nonselective alpha1 antagonists such as prazosin and terazosin, with fewer side effects.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/chemical synthesis , Dihydropyridines/chemical synthesis , Piperidines/chemical synthesis , Prostatic Hyperplasia/drug therapy , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding, Competitive , Blood Pressure/drug effects , Cell Line , Dihydropyridines/chemistry , Dihydropyridines/metabolism , Dihydropyridines/pharmacology , Dogs , Drug Evaluation, Preclinical , Humans , In Vitro Techniques , Male , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/metabolism , Muscle, Smooth/physiology , Piperidines/chemistry , Piperidines/metabolism , Piperidines/pharmacology , Prostate/drug effects , Prostate/metabolism , Prostate/physiology , Rats , Receptors, Adrenergic, alpha-1/metabolism , Recombinant Proteins/metabolism , Stereoisomerism , Structure-Activity Relationship
12.
J Med Chem ; 41(14): 2643-50, 1998 Jul 02.
Article in English | MEDLINE | ID: mdl-9651170

ABSTRACT

A number of novel dihydropyridine derivatives based upon 1, 4-dihydro-3-(methoxycarbonyl)-2, 6-dimethyl-4-(4-nitrophenyl)-5-((3-(4, 4-diphenylpiperidin-1-yl)propyl)aminocarbonyl)pyridine (4) have been synthesized and tested at cloned human alpha adrenoceptors as well as the rat L-type calcium channel. Within this compound series, 5-(aminocarbonyl)-1,4-dihydro-2, 6-dimethyl-4-(4-nitrophenyl)-3-((3-(4, 4-diphenylpiperidin-1-yl)propyl)aminocarbonyl)pyridine (19) displayed good binding affinity and selectivity for the alpha1a adrenoceptor (pKi = 8.73) and potently inhibited (pA2 = 9.23) phenylephrine-induced contraction of the human prostate.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Phenylephrine/pharmacology , Piperidines , Prostate/drug effects , Pyridines , Receptors, Adrenergic, alpha-1/drug effects , Aged , Aged, 80 and over , Animals , Brain/drug effects , Brain/metabolism , Calcium Channels/drug effects , Humans , In Vitro Techniques , Male , Middle Aged , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Muscle, Smooth/physiopathology , Piperidines/chemical synthesis , Piperidines/metabolism , Piperidines/pharmacology , Prostate/physiopathology , Prostatic Hyperplasia/physiopathology , Pyridines/chemical synthesis , Pyridines/metabolism , Pyridines/pharmacology , Rats
13.
Eur J Pharmacol ; 348(2-3): 287-95, 1998 May 08.
Article in English | MEDLINE | ID: mdl-9652345

ABSTRACT

L-762,459 ((+/-)1-(3-¿[5-carbamoyl-2-2-[(4-hydroxy-3-iodobenzimidoyl)-amino] -ethoxy-methy¿-6-methyl-4-(4-nitropheny)-1,4-dihydropyridine -3-carbonyl]-amino¿-propyl)-4-phenyl-1-piperidine-4-carboxylic acid methyl ester), an analog of a series of dihydropyridines previously reported to be selective alpha1A-adrenoceptor subtype antagonists was found to have alpha1A-adrenoceptor subtype selectivity (Ki (nM), la = 1.3, lb = 240, Id = 280). Specific [125I]L-762,459 binding was detected in rat cerebral cortex, hippocampus, vas deferens, kidney, heart and prostate tissues known to contain the alpha1A-adrenoceptor subtype, but not in tissues known to contain alpha1B-adrenoceptor (spleen, liver) and alpha1D-adrenoceptor (aorta). Scatchard analysis of [125I]L-762,459 binding in rat cerebral cortex and prostate indicated a single binding site with a Kd of 0.7 nM and Bmax of 11 (cerebral cortex) and 1 (prostate) pmole/g tissue. Specific and saturable [125I]L-762,459 binding was also found in human cerebral cortex, liver, prostate and vas deferens (Kd = 0.2-0.4 nM, Bmax = 0.4-4 pmole/g tissue). The specific binding in rat and human tissues was competed by non-selective alpha1-adrenoceptor compounds (Ki values in nM: prazosin (0.14-1.2), terazosin (1.8-5.9) and phentolamine (2.4-11)) and selective alpha1A-adrenoceptor compounds [Ki values in nM: (+) niguldipine (0.04-1.2) and SNAP 5399 ((+/-)-2-((2-aminoethyl)oxy)methyl-5-carboxamido-6-ethyl-4-(4-nitropheny l)-3-N-(3-(4,4-diphenylpiperidin-1-yl)propyl)carboxamido-1,4-dihyd ropyridine hydrate (0.5-4.8)]. The results were consistent with the selective binding of [125I]L-762,459 to the alpha1A-adrenoceptor. The specific labeling of the alpha1A-adrenoceptor subtype by [125I]L-762,459 may make it a useful tool to localize the distribution of the alpha1A-adrenoceptor.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/metabolism , Amidines/metabolism , Dihydropyridines/metabolism , Animals , Binding, Competitive , Cerebral Cortex/metabolism , Hippocampus/metabolism , Humans , Iodine Radioisotopes , Kidney/metabolism , Male , Myocardium/metabolism , Phentolamine/metabolism , Piperidines/metabolism , Prazosin/analogs & derivatives , Prazosin/metabolism , Prostate/metabolism , Radioligand Assay , Rats , Receptors, Adrenergic, alpha-1 , Structure-Activity Relationship , Vas Deferens/metabolism
14.
Nature ; 396(6712): 674-9, 1998 Dec 17.
Article in English | MEDLINE | ID: mdl-9872315

ABSTRACT

The principal inhibitory neurotransmitter GABA (gamma-aminobutyric acid) exerts its effects through two ligand-gated channels, GABA(A) and GABA(C) receptors, and a third receptor, GABA(B) , which acts through G proteins to regulate potassium and calcium channels. Cells heterologously expressing the cloned DNA encoding the GABA(B)R1 protein exhibit high-affinity antagonist-binding sites, but they produce little of the functional activity expected from studies of endogenous GABA(B) receptors in the brain. Here we describe a new member of the GABA(B) polypeptide family, GABA(B)R2, that shows sequence homology to GABA(B)R1. Neither GABA(B)R1 nor GABA(B)R2, when expressed individually, activates GIRK-type potassium channels; however, the combination of GABA(B)R1 and GABA(B)R2 confers robust stimulation of channel activity. Both genes are co-expressed in individual neurons, and both proteins co-localize in transfected cells. Moreover, immunoprecipitation experiments indicate that the two polypeptides associate with each other, probably as heterodimers. Several G-protein-coupled receptors (GPCRs) exist as high-molecular-weight species, consistent with the formation of dimers by these receptors, but the relevance of these species for the functioning of GPCRs has not been established. We have now shown that co-expression of two GPCR structures, GABA(B)R1 and GABA(B)R2, belonging to the same subfamily is essential for signal transduction by GABA(B) receptors.


Subject(s)
Receptors, GABA-B/metabolism , Receptors, GABA , Amino Acid Sequence , Animals , Blotting, Western , CHO Cells , COS Cells , Cell Line , Cricetinae , GABA-B Receptor Agonists , GABA-B Receptor Antagonists , Hypothalamus/metabolism , Male , Molecular Sequence Data , Mutation , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, GABA-B/genetics , Transfection , Xenopus
15.
J Med Chem ; 35(12): 2293-306, 1992 Jun 12.
Article in English | MEDLINE | ID: mdl-1613753

ABSTRACT

A series of stilbenes has been prepared and tested for cytotoxicity in the five human cancer cell lines A-549 non-small cell lung, MCF-7 breast, HT-29 colon, SKMEL-5 melanoma, and MLM melanoma. The cis stilbenes 6a-f proved to be cytotoxic in all five cell lines, with potencies comparable to that of combretastatin A-4. These cytotoxic compounds were all potent inhibitors of tubulin polymerization. The corresponding trans stilbenes 7b-f were inactive as tubulin polymerization inhibitors and were significantly less cytotoxic in the five cancer cell lines. In the dihydro series, 8b, 8c, and 8f were inactive as tubulin polymerization inhibitors, while 8a, 8d, and 8e were less active than the corresponding cis compounds 6a, 6d, and 6e. The lack of tubulin polymerization inhibitory activity and cytotoxicity displayed by the phenanthrene 23b, which was synthesized as a conformationally rigid analogue of the lead compound 1, indicates that the activity of the stilbenes is not due to a totally planar conformation. Similarly, inactivity of the conformationally restricted analogue 26 suggests that the biologically active conformation of 1a resembles that of the cis alkene 1. Additional inactive compounds prepared include the benzylisoquinoline series 28-32 as well as the protoberberines 38 and 39. Shortening the two-carbon bridge of 1a to a one-carbon bridge in the diphenylmethane 20 resulted in a decrease in cytotoxicity and tubulin polymerization inhibitory activity. Although the corresponding benzophenone 18 was as active as 1a as a tubulin polymerization inhibitor, it was less cytotoxic than 1a, and the benzhydrol 19 was essentially inactive. With the exception of the amide 15c, which displayed low antitubulin activity, all of the phenylcinnamic acid derivatives 14a-c and 15a-f were inactive in the tubulin polymerization inhibition assay. The acid 14b and the ester 15a were cytotoxic in several of the cancer cell cultures in spite of their inactivity as tubulin polymerization inhibitors.


Subject(s)
Antineoplastic Agents/chemical synthesis , Stilbenes/chemistry , Stilbenes/chemical synthesis , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Cell Division/drug effects , Colonic Neoplasms/drug therapy , Humans , Lung Neoplasms/drug therapy , Melanoma/drug therapy , Stilbenes/pharmacology , Stilbenes/therapeutic use , Structure-Activity Relationship , Tubulin/metabolism , Tubulin Modulators , Tumor Cells, Cultured
16.
J Nat Prod ; 54(6): 1656-60, 1991.
Article in English | MEDLINE | ID: mdl-1812215

ABSTRACT

An array of 55 flavones having a variety of substituents was evaluated for cytotoxicity in five cancer cell cultures: A-549 lung carcinoma, MCF-7 breast carcinoma, HT-29 colon adenocarcinoma, SKMEL-5 melanoma, and MLM melanoma. Fifteen of the 55 flavone derivatives were significantly active against at least one of these cell cultures, and 4'-[(t-butyldi-methylsily)oxy]-7,8-dihydroxy-3',5'- dimethoxyflavone [40] was the most active of all. Structure-activity relationships of these compounds are discussed.


Subject(s)
Antineoplastic Agents/pharmacology , Flavonoids/pharmacology , Antineoplastic Agents/chemistry , Drug Screening Assays, Antitumor , Flavonoids/chemistry , Structure-Activity Relationship , Tumor Cells, Cultured
17.
J Nat Prod ; 54(5): 1345-52, 1991.
Article in English | MEDLINE | ID: mdl-1800636

ABSTRACT

An array of hydroxylated flavones and related compounds was synthesized and evaluated for inhibition of the in vitro protein-tyrosine kinase activity of p56lck, an enzyme that is thought to play a key role in mediating signal transduction from the CD4 receptor during lymphocyte activation. In general, the most active compounds had hydroxyl groups on both the A and C rings. At least two hydroxyl groups were required for good inhibitory activity, and the relative positions of these groups played an important role in determining potency. Compounds without hydroxyl groups were inactive as inhibitors.


Subject(s)
Flavonoids/chemical synthesis , Protein-Tyrosine Kinases/antagonists & inhibitors , Flavonoids/pharmacology , Hydroxylation , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
18.
J Med Chem ; 34(8): 2579-88, 1991 Aug.
Article in English | MEDLINE | ID: mdl-1875350

ABSTRACT

An array of cis-, trans-, and dihydrostilbenes and some N-arylbenzylamines were synthesized and evaluated for their cytotoxicity in the five cancer cell cultures A-549 lung carcinoma, MCF-7 breast carcinoma, HT-29 colon adenocarcinoma, SKMEL-5 melanoma, and MLM melanoma. Several cis-stilbenes, structurally similar to combretastatins, were highly cytotoxic in all five cell lines and these were also found to be active as inhibitors of tubulin polymerization. The most active compounds also inhibited the binding of colchicine to tubulin. The most potent of the new compounds, both as a tubulin polymerization inhibitor and as a cytotoxic agent, was (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene (5a). This substance was almost as potent as combretastatin A-4 (1a), the most active of the combretastatins, as a tubulin polymerization inhibitor. Compound 5a was found to be approximately 140 times more cytotoxic against HT-29 colon adenocarcinoma cells and about 10 times more cytotoxic against MCF-7 breast carcinoma cells than combretastatin A-4. However, 5a was found to be about 20 times less cytotoxic against A-549 lung carcinoma cells, 30 times less cytotoxic against SKMEL-5 melanoma cells, and 7 times less cytotoxic against MLM melanoma cells than combretastatin A-4. The relative potencies 5a greater than 8a greater than 6a for the cis, dihydro, and trans compounds, respectively, as inhibitors of tubulin polymerization are in agreement with the relative potencies previously observed for combretastatin A-4 (1a), dihydrocombretastatin A-4 (1c), and trans-combretastatin A-4 (1b). The relative potencies 5a greater than 8a greater than 6a were also reflected in the results of the cytotoxicity assays. Structure-activity relationships of this group of compounds are also discussed.


Subject(s)
Antineoplastic Agents/chemical synthesis , Stilbenes/chemical synthesis , Tubulin Modulators , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Breast Neoplasms/drug therapy , Chemical Phenomena , Chemistry , Colchicine/metabolism , Colonic Neoplasms/drug therapy , Humans , Lung Neoplasms/drug therapy , Melanoma/drug therapy , Molecular Structure , Polymers/metabolism , Stilbenes/therapeutic use , Structure-Activity Relationship , Tubulin/metabolism , Tumor Cells, Cultured
19.
J Med Chem ; 34(2): 798-806, 1991 Feb.
Article in English | MEDLINE | ID: mdl-1995903

ABSTRACT

Treatment of o-hydroxyacetophenones 2a-e with excess lithium bis(trimethylsilyl)amide followed by dialkyl carbonates gave alkyl 3-(2-hydroxyaryl)-3-oxopropanoates 3a-e. The latter substances were transformed through the reaction of their magnesium chelates with benzoyl chlorides into a series of 3-(alkoxycarbonyl)-2-arylflavones, which were subsequently elaborated into a variety of flavonoids. These compounds were tested for their abilities to inhibit the in vitro protein-tyrosine kinase activity of p56lck, an enzyme which is thought to play a key role in mediating signal transduction from the CD4 receptor during lymphocyte activation. All of the active compounds had either an amino or a hydroxyl substituent at the 4'-position of the 2-aryl ring. The most active substance prepared in this study is compound 17c, which is approximately 1 order of magnitude more potent than the natural product quercetin (1). Compound 17c was a competitive inhibitor of p56lck with respect to ATP and was highly selective for the inhibition of protein-tyrosine over protein-serine/threonine kinases.


Subject(s)
Flavonoids/chemical synthesis , Protein-Tyrosine Kinases/antagonists & inhibitors , Chemical Phenomena , Chemistry , Flavonoids/pharmacology , Genistein/analogs & derivatives , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...